🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Prince of MetALD shared his insights and they cannot be missed! 📊 PEth increasingly used to diagnose under-recognized ALD within MetALD 📏 Quantity of Alcohol, AUDIT-C, and DSM-V criteria can be used for MetALD assessment 🔍 Check out research gaps in this evolving field

Always proud of Luis Antonio Díaz, MD for his great achievements! A real rising star of world hepatology

The Global Think-tank on Steatotic Liver Disease is proud to announce two groundbreaking publications: The People-First Liver Charter, in Nature Medicine nature.com/articles/s4159… 2. A call for doubling the MASH diagnostic rate: thelancet.com/journals/lanep… #SLDthinktank #LiverTwitter

And we are thrilled to see the coverage of steatotic liver disease today in the The Guardian! theguardian.com/society/2025/j… Naim Alkhouri Jörn Schattenberg Dídac Mauricio Luis Antonio Díaz, MD Scott Isaacs Paul Brennan #SLDthinktank #LiverTwitter

Daniel Velázquez Cortés Thanks for joining us at the #SLDthinktank Daniel Velázquez Cortés It had extensive media coverage: theguardian.com/society/2025/j… lavanguardia.com/vida/20250606/… And we launched the People-First Liver Charter: nature.com/articles/s4159… Nature Medicine Naim Alkhouri Jörn Schattenberg #LiverTwitter

Our new paper on Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with MASH: a randomised, phase 2a trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa… Manuel Romero-Gómez Daniel Huang Naim Alkhouri Mazen Noureddin, MD, MHSc Quentin M. Anstee Christopher A. Longhurst, MD

✅ out this month’s issue‼️ Learn about:  📑 Role of muscle in MASLD❓ 📑 Optimal AFP cut-off in HCC screening in cured HCV?❓ 📑 Min meaningful diff in PROs in cirrhosis❓ 📑 How well are we treating itch in PSC❓ 📑 How best to 🔍 fibrosis in MetALD❓ journals.lww.com/hepcomm/pages/…

🚨Finally out in Journal of Hepatology 🚨 Our new paper explores the clinical utility of PEth🍷 to detect underreported alcohol use and enhance SLD subclassification. A huge thanks🙏 to my mentor Rohit Loomba for the opportunity to lead this project! 📖 Read more: doi.org/10.1016/j.jhep…

New data w/Rohit Loomba MASLD Research Center on extended-release naltrexone (XR-NTX) in advanced ALD: In this case series, XR-NTX was well tolerated in patients with compensated ALD (64% cirrhosis)— no hepatotoxicity, no severe adverse events. 👉 doi.org/10.1111/apt.70… #LiverTwitter

New data Luis Antonio Díaz, MD MASLD Research Center on use of once monthly injectable naltrexone in patients with advanced ALD -Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of AUD in Adv… pubmed.ncbi.nlm.nih.gov/40515940/ AASLD

Keep it up Luis Antonio Díaz, MD ! This is a key piece that other liver centers can use to change their protocol to give injectable once a month naltrexone to their advanced ALD patients before discharge from the hospital.

Recientemente publicamos un artículo de la nueva nomenclatura de MASLD en Español con Manuel Romero-Gómez y Sebastian Ferretti en Medicina Clínica Acá el link gratuito: authors.elsevier.com/c/1lFjD5t595plc Los invito a leerlo!

Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis - Still much work to do in this field- CGH cghjournal.org/article/S1542-…

🎙️ Join us for a free webinar! 🗓️ Tuesday, July 1, 2025 🕚 11:00 AM – 01:00 PM (EDT, New York, USA) 🔬 Topic: #MetALD – Opportunities and Challenges 🪑 Chairs: Prof. Ashwani K. Singal & Prof. Robert J. Wong 📌 Free registration now open: oaepublish.com/webreviewer/mt… #Livertwitter

A stepwise, noninvasive strategy with FIB-4 followed by VCTE accurately identifies fibrosis risk in people with suspected #MetALD, helping to catch more cases and reduce missed diagnoses. journals.lww.com/hepcomm/Fullte…

Thanks for highlighting Luis Antonio Díaz, MD work MASLD Research Center UCSD Gastroenterology !

🚨GI/Hep Fellowships start next week‼️ Hepatology Communications has the 📑 you need to thrive 💫 #GIHepFellowshipBootcamp First up, you get a consult for a #LiverMass, ✅ out this review about benign liver masses❕ 📍Hemangiomas 📍FNH 📍Hepatic Adenomas 📍Cysts journals.lww.com/hepcomm/fullte…

JCI - Therapeutic horizons in metabolic dysfunction–associated steatohepatitis. Delighted to write this with ⁦Rohit Loomba⁩ ⁦King's College London⁩ ⁦The Roger Williams Institute of Liver Studies⁩ King's jci.org/articles/view/…

🥇🔬UC San Diego is ranked #1 among the best universities for Gastroenterology and Hepatology Research by U.S. News & World Report! Proud of the Division of Gastroenterology and Hepatology for outstanding innovation and impact. UCSD Gastroenterology MASLD Research Center #ResearchExcellence

Go team ⁦UCSD Gastroenterology⁩ ! Terrific achievement and a brilliant team effort!!! ⁦MASLD Research Center⁩ ⁦Bernd Schnabl⁩ ⁦Veeral Ajmera⁩ ⁦Michael V. Drake⁩ ⁦Christopher A. Longhurst, MD⁩ ⁦EASLnews⁩ ⁦INASL⁩ ⁦⁩ ⁦Grace Su⁩ ⁦San Diego Digestive Diseases Research Center⁩